Literature DB >> 22934850

Past, present and future strategies of immunotherapy in gynecological malignancies.

F Bellati1, C Napoletano, I Ruscito, V Visconti, M Antonilli, M L Gasparri, I G Zizzari, H Rahimi, I Palaia, A Rughetti, P Benedetti Panici, M Nuti.   

Abstract

Recently, the combining of different drugs has greatly improved response and survival rates in gynecological malignancies. Results are however far from being satisfactory. Treatments used in case of advanced or recurrent disease offer limited results in terms of long-term responses. The urgent need for new and more effective treatments has prompted researchers to investigate and propose new therapeutic strategies. One of the most interesting approaches that are being explored is constituted by immunotherapy. Currently, immunotherapeutic strategies include vaccination with peptide, viral vectors, carbohydrates and antiidiotypic antibodies. In addition, cell based immunotherapy has been adopted in vitro activated lymphocytes and dendritic cells. Most experience has been acquired in ovarian cancer and cervical cancer. Little has been investigated in endometrial and rare gynecologic neoplasms.The clinical experiences and results achieved with immunotherapy in this setting of patients have been reviewed and the future avenues that are currently being explored have also been discussed.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22934850     DOI: 10.2174/1566524011313040014

Source DB:  PubMed          Journal:  Curr Mol Med        ISSN: 1566-5240            Impact factor:   2.222


  6 in total

Review 1.  Updates in systemic treatment for metastatic cervical cancer.

Authors:  Angel Chao; Cheng-Tao Lin; Chyong-Huey Lai
Journal:  Curr Treat Options Oncol       Date:  2014-03

Review 2.  Circulating tumor cells as trigger to hematogenous spreads and potential biomarkers to predict the prognosis in ovarian cancer.

Authors:  Maria Luisa Gasparri; Delia Savone; Raad Aris Besharat; Ammad Ahmad Farooqi; Filippo Bellati; Ilary Ruscito; Pierluigi Benedetti Panici; Andrea Papadia
Journal:  Tumour Biol       Date:  2015-10-26

3.  CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase inhibition in advanced serous ovarian cancer.

Authors:  Holger Bronger; Judith Singer; Claudia Windmüller; Ute Reuning; Daniela Zech; Claire Delbridge; Julia Dorn; Marion Kiechle; Barbara Schmalfeldt; Manfred Schmitt; Stefanie Avril
Journal:  Br J Cancer       Date:  2016-08-04       Impact factor: 7.640

4.  Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: Clinical and immunological data of a phase I/II clinical trial.

Authors:  Morena Antonilli; Hassan Rahimi; Valeria Visconti; Chiara Napoletano; Ilary Ruscito; Ilaria Grazia Zizzari; Salvatore Caponnetto; Giacomo Barchiesi; Roberta Iadarola; Luca Pierelli; Aurelia Rughetti; Filippo Bellati; Pierluigi Benedetti Panici; Marianna Nuti
Journal:  Int J Oncol       Date:  2016-02-08       Impact factor: 5.650

5.  Immunobiology of Solid Cancers: Cellular and Molecular Pathways as Potential Diagnostic and Therapeutic Targets.

Authors:  Ilary Ruscito; Elena Ioana Braicu; Maria Luisa Gasparri; Ilaria Grazia Zizzari
Journal:  Biomed Res Int       Date:  2018-03-01       Impact factor: 3.411

6.  PI3K/AKT/mTOR Pathway in Ovarian Cancer Treatment: Are We on the Right Track?

Authors:  Maria Luisa Gasparri; Erlisa Bardhi; Ilary Ruscito; Andrea Papadia; Ammad Ahmad Farooqi; Claudia Marchetti; Giorgio Bogani; Irene Ceccacci; Michael D Mueller; Pierluigi Benedetti Panici
Journal:  Geburtshilfe Frauenheilkd       Date:  2017-10-26       Impact factor: 2.915

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.